FDA approval
| 3 min read
A new compound, Vykat XR, addresses insatiable hunger in the rare genetic condition, offering relief for patients and hope for families.
| 5 min read
Highlights from AACR 2025, COVID-19 vaccine flip flops, an FDA approval for a rare skin disorder, and more led biotech and pharma news this week.
| 5 min read
Stem cell therapy for Parkinson’s disease, discontinuation of Pfizer’s GLP-1 drug, a pig liver clinical trial, and more biotech and pharma news from this week.
| 4 min read
From layoffs at the FDA, CDC, and NIH to a blood test for Alzheimer’s disease and a starfish-inspired diagnostic, the DDN team breaks down this week’s news.
| 3 min read
Vertex Pharmaceuticals’ drug, Journavx, blocks a sodium channel outside of the brain. Experts hope that this non-addictive pain drug may be the first of many.
| 3 min read
The gene therapy treats the rare genetic disease AADC deficiency by delivering a functional gene into the brain.
| 3 min read
The FDA approved two new medications for Niemann-Pick disease type C that improve symptoms, showing the power of community advocacy.
| 3 min read
Sulopenem becomes the first oral penem antibiotic approved in the United States, expanding non-IV treatment options for UTIs.
Page 1 of 1 - 8 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Reliable fluid biomarkers strategies for clinical neuroscience research
Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Understanding drug impurities: types, sources, and analytical strategies
Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Discovering cutting-edge nitrosamine analysis in pharmaceuticals
New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
